-

Shareholder Alert: Robbins LLP is Investigating the Officers and Directors of Berry Corporation (BRY) on Behalf of Shareholders

SAN DIEGO & DALLAS--(BUSINESS WIRE)--Shareholder rights law firm Robbins LLP informs shareholders that it is investigating Berry Corporation (NYSE: BRY) for potential material misstatements and violations of federal securities laws pursuant to its July 2018 initial public offering ("IPO"). On July 30, 2018, Berry completed its IPO offering shares at $14 per share and raising $112 million in net proceeds. Since its IPO, Berry's stock has precipitously declined and by June 29, 2020, shares of Berry closed at only $4.76 per share, representing a staggering decline of approximately 66% from its IPO share price.

If you purchased shares of Berry stock in its July 2018 IPO at $14 per share, click here.

Berry Corporation (BRY) Shareholders Have Legal Options

Contact us to learn more:
Leo Kandinov
(800) 350-6003
LKandinov@robbinsllp.com
Shareholder Information Form

Want to be notified if a class action against Berry settles? Want to receive free alerts about companies engaged in wrongdoing? Sign up for Stock Watch today.

Attorney Advertising. Past results do not guarantee a similar outcome.

Contacts

Leo Kandinov
Robbins LLP
5040 Shoreham Place
San Diego, CA 92122
LKandinov@robbinsllp.com
(619) 525-3990 or Toll Free (800) 350-6003
www.robbinsllp.com

Industry:

Robbins LLP

NYSE:BRY
Release Versions
English
$Cashtags
$BRY
Hashtags
#ClassAction
#Finance
#Investment
#Investor
#Lawsuit
#Securities
#Shareholder
#Shareholderrights
#StockAlert
#StockMarketData
#StockNews
#StockTrading
#Stocks
#Trader
#shareholderrightslawfirm

Contacts

Leo Kandinov
Robbins LLP
5040 Shoreham Place
San Diego, CA 92122
LKandinov@robbinsllp.com
(619) 525-3990 or Toll Free (800) 350-6003
www.robbinsllp.com

More News From Robbins LLP

Investor Notice: Robbins LLP Informs Investors of the ADMA Biologics, Inc. Class Action Lawsuit

SAN DIEGO--(BUSINESS WIRE)--Robbins LLP informs stockholders that a class action was filed on behalf of all investors who purchased or otherwise acquired ADMA Biologics, Inc. (NASDAQ: ADMA) securities between August 9, 2024 and March 25, 2026. ADMA Biologics, Inc., a biopharmaceutical company, develops, manufactures, and markets specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally.For more information, submit...

Investor Notice: Robbins LLP Informs Investors of the Erasca, Inc. Class Action Lawsuit

SAN DIEGO--(BUSINESS WIRE)--Robbins LLP informs stockholders that a class action was filed on behalf of all investors who purchased or otherwise acquired Erasca, Inc. (NASDAQ: ERAS) securities between January 14, 2025 and April 26, 2026. Erasca, Inc., a clinical-stage precision oncology company, focuses on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers.For more information, submit a form, email attorney Aaron Dumas, Jr., or give us a call...

Robbins LLP is Investigating Allegations that the Officers and Directors of Blaize Holdings, Inc. (BZAI) Violated Securities Laws and Breached Fiduciary Duties to Shareholders

SAN DIEGO--(BUSINESS WIRE)--Shareholder rights law firm Robbins LLP is investigating Blaize Holdings, Inc. (NASDAQ: BZAI) to determine whether certain Blaize Holdings, Inc. officers and directors violated securities laws and breached fiduciary duties to shareholders. Blaize Holdings, Inc. provides artificial intelligence (AI)-enabled edge computing solutions.In late April 2026, two separate short-seller reports were published within two days of each other, both raising concerns regarding Blaize’...
Back to Newsroom